# SS Innovations International, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/SS Innovations International, Inc.). ## Overview SS Innovations International, Inc. develops, manufactures, and sells the SSi Mantra surgical robotic system and related SSi Mudra instruments and accessories. The company is based in the United States but its manufacturing and commercial footprint is centered in India, with sales and support activities extending into selected international markets. ## Products & services • SSi Mantra surgical robotic system • SSi Mudra surgical instruments and accessories • System sales under outright purchase, installment, and pay-per-procedure models • Installation, maintenance, and 24/7 technical support • Surgeon and staff training, proctoring, and onboarding services - **Surgical robotic systems** (90%) — The SSi Mantra robotic platform sold to hospitals and surgical centers. - **Instruments and accessories** (7%) — Reusable and consumable instruments, accessories, and stocking orders for installed systems. - **Warranty and service revenue** (2%) — Warranty coverage, readiness support, maintenance plans, and technical support services. - **Lease and pay-per-procedure income** (1%) — Recurring income from systems placed under usage-based or deferred commercial models. - SSi Mantra surgical robotic system - SSi Mudra surgical instruments and accessories - Outright purchase, installment, and pay-per-procedure sales models - Installation, repair, maintenance, and technical support - Surgeon training, proctoring, and onboarding services ## Customers Customers are hospitals, surgical centers, and physicians that acquire robotic surgery systems for use in urology, general surgery, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac procedures. The company also serves customers that prefer usage-based or deferred payment structures, which lowers upfront adoption barriers for capital-constrained healthcare providers. - **Hospitals and surgical centers** (primary) — Buy SSi Mantra systems for operating room use across multiple specialties and to build robotic surgery programs. - **Physicians and surgical teams** (secondary) — Use the platform and buy into training, proctoring, and support services to adopt robotic procedures. - **Installed-base customers** (primary) — Reorder instruments, accessories, warranty coverage, and maintenance services after system installation. - **Usage-based customers** (secondary) — Adopt pay-per-procedure or deferred models to access the system with lower upfront capital needs. - Hospitals buying robotic systems for multi-specialty surgery programs - Surgical centers seeking lower-cost access to robotic surgery - Physicians and care teams needing training and proctoring support - Customers using pay-per-procedure models to reduce upfront capex - Installed-base customers ordering instruments and accessories repeatedly ## Geography Substantially all reported sales have been in India, with additional individual sales in the United Arab Emirates, Ecuador, Iraq, Nepal, Colombia, Indonesia, and the Philippines. Manufacturing operations are based in India, which also supports the company’s service network and distributor relationships. - India is the core commercial market and installed-base center - Manufacturing operations are based in India - Sales have also been made in the UAE, Ecuador, Iraq, and Nepal - Additional sales have been made in Colombia, Indonesia, and the Philippines - Global distributors and field service engineers support international rollout ## Strategy The company’s strategy is to expand access to surgical robotics by offering a lower-cost, next-generation system with flexible commercial models. It is also building recurring revenue through instruments, accessories, service plans, and usage-based arrangements while broadening regulatory approvals and market reach. - **Expand installed base of SSi Mantra** (medium-term) — A larger installed base supports system sales, instrument pull-through, and service revenue. - **Increase recurring revenue mix** (medium-term) — Instruments, accessories, warranty, and service plans create repeat revenue after system placement. - **Broaden product portfolio** (medium-term) — New instruments and specialty applications increase the number of procedures the platform can support. - **Expand regulatory and market access** (long-term) — Approvals are needed to sell in regulated markets and to scale beyond current geographies. - Expand adoption of SSi Mantra in India and selected global markets - Use flexible selling models to reduce customer adoption barriers - Grow recurring revenue from instruments, accessories, and services - Broaden product capability with new instruments and specialty use cases - Secure regulatory approvals to enter additional regulated markets ## Risks The business depends on continued adoption of a relatively new robotic platform, successful regulatory approvals, and the ability to finance growth. It also faces execution risk around manufacturing, service quality, and customer uptake of alternative payment models, along with the usual risks of a capital-intensive medical device company. - **Regulatory approval delays or denials** [high] — Sales in regulated markets depend on obtaining and maintaining approvals for the robotic system and related devices. - **Financing and liquidity dependence** [high] — The company has relied on debt and equity offerings and may need additional capital to fund operations and expansion. - **Commercial adoption risk** [medium] — Robotic surgery adoption depends on surgeon acceptance, hospital budgets, and willingness to switch from established systems. - **Manufacturing and service execution risk** [medium] — The model requires reliable production, installation, maintenance, and technical support to protect customer uptime. - **Geographic concentration in India** [high] — Substantially all sales have been in India, so demand or policy changes there would affect results disproportionately. - Early-stage commercialization risk if adoption is slower than expected - Regulatory approval risk in markets where the company wants to sell - Funding risk because growth has relied on external capital - Execution risk in manufacturing, installation, and field service - Customer concentration and geography concentration in India ## Accounting Revenue recognition is a key accounting issue because the company sells systems outright, on installment terms, and on a pay-per-procedure basis, which can shift timing between upfront and over-time recognition. Investors should also watch stock-based compensation, fair value estimates, and the going-concern assumption, since these can materially affect reported losses and balance sheet presentation. - **Revenue recognition for mixed commercial models** — System sales, lease income, and recurring service revenue - **Standalone selling price allocation** — Reported mix and timing of revenue - **Stock-based compensation** — Operating expenses and net loss - **Going-concern and financing assumptions** — Liquidity disclosures and investor risk assessment - Revenue timing differs by outright sale, installment, and pay-per-procedure model - Bundled system, instrument, accessory, and service contracts require allocation - Lease-income treatment applies when systems are placed on usage-based terms - Stock-based compensation depends on valuation assumptions and vesting estimates - Going-concern assessment reflects dependence on future financing --- *Last updated: 2026-04-29T04:56:23.049075+00:00*